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Efficacy of canakinumab as first-line
biologic agent in adult-onset Still’s disease
Giulio Cavalli1,2,3* , Alessandro Tomelleri1,2, Giacomo De Luca1,2, Corrado Campochiaro1, Charles A. Dinarello3,4,
Elena Baldissera1 and Lorenzo Dagna1,2
Adult-onset Still’s disease (AOSD) is a rare condition
characterized by fever, arthritis, skin rash, and
multi-organ inflammation. The pathogenesis is medi-
ated by the pro-inflammatory cytokine interleukin
(IL)-1β, as confirmed by the clinical efficacy of se-
lective blockade. Anakinra, a recombinant inhibitor
of the IL-1β receptor, currently represents the
cornerstone of biologic therapy [1].
More recently, a monoclonal antibody blocking IL-1β,
canakinumab, entered the clinical arena and became available
for the treatment of AOSD. The efficacy of canakinumab in
AOSD is being evaluated in a clinical trial (NCT022042939).
At present, evidence from several case reports or series sug-
gest good efficacy in AOSD (reviewed in [2, 3]): of note, in all
published cases, canakinumab was used following failure of
one or more biologics, including anakinra.
Here, we report the efficacy of canakinumab as a
first-line biologic agent in AOSD. Four patients with severe
DMARD-refractory AOSD received canakinumab (4mg/
kg/4 weeks) following failure of conventional treatment
with corticosteroids and methotrexate. Patient characteris-
tics and response to therapy are shown in Table 1. In all pa-
tients, treatment with canakinumab led to striking clinical
responses, within days of initiation. Fever and skin rash dis-
appeared first, followed by progressive improvement in
arthritis. If present, inflammatory organ involvement also
responded to treatment, as confirmed by resolution of peri-
cardial inflammation and hepatosplenomegaly in two and
one patients, respectively. Marked reductions in CRP, ESR,
and serum ferritin mirrored the efficacy on clinical manifes-
tations. Reduced disease severity allowed for robust tapering
of corticosteroid therapy, which was discontinued in two pa-
tients and substantially reduced in two patients (Table 1).
Biologic therapy with IL-1 inhibitors should be instituted
earlier in AOSD course for more favorable outcomes [2].
Both IL-1 blocking agents anakinra and canakinumab re-
ceived EMA approval for the treatment of AOSD. Al-
though anakinra and canakinumab block the same target,
they have different mechanisms of action. Anakinra, a re-
combinant inhibitor of the IL-1 receptor, requires daily in-
jections due to a short half-life of 6 h. Canakinumab, a fully
human monoclonal antibody selectively blocking IL-1β, has
a longer half-life and is administered monthly [4].
In this study, first-line biologic therapy of AOSD
with canakinumab resulted in rapid and marked effi-
cacy, ultimately leading to full clinical remissions in
all patients and allowing for robust steroid-sparing ef-
fects. Canakinumab in AOSD is often used as a last
line of treatment following failure of multiple other
agents, including anakinra [2]. Early treatment is
nevertheless advisable and may reduce chances of
chronic disease and permanent damage [2, 5].
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Table 1 Patient characteristics and response to therapy
Clinical
features
AOSD
course
Therapy before
CAN (mg)
Lab tests
before CAN
Therapy after
CAN (mg)
Lab tests
after CAN
Response
to CAN
Modified Pouchot
score before CAN
Modified Pouchot
score after CAN
Side
effect
A, M, R,
F, S
SD PDN (15)
MTX (20)
ESR 40
CRP 31.5
Ferritin 715
MTX (20) ESR 12
CRP 4.2
Ferritin 140
Complete 7 1 None
A, M, R,
F, HSM
SD PDN (25) MTX
(20)
ESR 45
CRP 8.2
Ferritin 880
PDN (5)
MTX (15)
ESR 7
CRP 3.7
Ferritin 135
Complete 6 2 None
A, M, F, L,
S
SD PDN (10)
MTX (10)
ESR 32
CRP 31.1
Ferritin 1324
– ESR 12
CRP 5.7
Ferritin 98
Complete 5 1 None
A, M, F,
P, R
SD PDN (25) MTX
(20)
ESR 57
CRP 17.4
Ferritin 1025
PDN (2.5)
MTX (20)
ESR 9
CRP 2.1
Ferritin 119
Complete 6 1 None
AOSD duration indicates duration of disease before initiation of canakinumab (CAN). Disease manifestations: A arthritis; M myalgia; F fever; R rash; P pharyngitis; S
serositis; L lymphadenopathies; HSM hepatosplenomegaly. Therapy before CAN indicates the treatment regimen that was being administered at the time of CAN
initiation; therapy after CAN indicates the maintenance therapy that was being administered at the last follow-up visit. PDN prednisone; MTX methotrexate; SD
systemic disease; ESR erythrocyte sedimentation rate (mm/1 h, normal values < 30mm/1 h); CRP C-reactive protein (mg/L, < 6 mg/L); ferritin (ng/mL, 15–150 ng/
mL). The modified Pouchot score for measuring AOSD disease activity evaluates clinical and laboratory manifestations and ranges from 0 to 12, with scores above
4 indicating active disease
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